Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

1.130 -0.100 (-8.13%)
Streaming Delayed Price Updated: 11:00 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AN2 Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Participate at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Participate at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.